By Scientia Professor Anthony D Kelleher

Journal articles

Lim H; Sedwell R; Duarte NL; Cooper DA; Kelleher AD; Carr AD; Mallon PW, 2005, 'Nucleoside reverse transcriptase inhibitor effects on adipocyte mitochondrial DNA quantity and quality in vitro', Antiviral Therapy, 10, pp. L41 - L42

Suzuki K; Shijuuku T; Fukamachi T; Zaunders J; Guillemin GJ; Cooper DA; Kelleher AD, 2005, 'Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region.', Journal of RNAi and Gene Silencing, 1, pp. 66 - 78

Emery S; Workman C; Puls R; Bloch M; Baker D; Bodsworth NJ; Anderson JA; Crowe SM; Hoy JF; Aichelburg A; Ward LA; Boyle D; Law MG; Kelleher AD; Cooper DA, 2005, 'Randomised, Placebo-Controlled, Phase 1/2a Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-y in HIV-1 Infected Subjects', Human Vaccines, 1, pp. 232 - 238, http://www.landesbioscience.com/journals/vaccines/emeryHV1-6.pdf

Sasson SC; Kelleher AD; Cooper DA, 2005, 'The modern ART of HIV infection management: Towards a tailored approach to maximize CD4 T cell reconstitution', Clinical Infectious Diseases, 41, pp. 373 - 375

Zaunders JJ; Dyer WB; Wang B; Munier ML; Miranda-Saksena M; Newton R; Moore J; Mackay CR; Cooper DA; Saksena NK; Kelleher AD, 2004, 'Identification of circulating antigen-specific CD4⁺ T lymphocytes with a CCR5⁺, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection', Blood, 103, pp. 2238 - 2247, http://dx.doi.org/10.1182/blood-2003-08-2765

Pett SL; Kelleher A, 2004, 'Antiretroviral therapy-induced immune restoration in HIV infection: A double-edged sword?', Expert Review of Anti-Infective Therapy, 2, pp. 335 - 339, http://dx.doi.org/10.1586/14787210.2.3.335

Mallon PW; Sedwell R; Unemori P; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'Changes in nuclear gene expression resulting from NRTI-induced inhibition of mitochondrial transcription reveal links between mitochondrial dysfunction and lipid metabolism', Antiviral Therapy, 9, pp. L56 - L56

Furutsuki T; Hosoya N; Kawana-Tachikawa A; Tomizawa M; Odawara T; Goto M; Kitamura Y; Nakamura T; Kelleher AD; Cooper DA; Iwamoto A, 2004, 'Frequent transmission of Cytotoxic-T-Lymphocyte escape mutants of human immunodeficiency virus type 1 in the highly HLA-A24-positive Japanese population', Journal of Virology, 78, pp. 8437 - 8445

Zaunders J; Dyer W; Wang B; Munier M; Miranda-Saksena M; Newton R; Moore JJ; MacKay CR; Cooper DA; Saksena NK; Kelleher AD, 2004, 'Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term non-progressor and in CMV infection', Blood, 8, pp. 2765 - 2765

Mallon PW; Unemori P; Sedwell R; Morey AL; Rafferty M; Williams KM; Chisholm DJ; Samaras K; Emery S; Kelleher AD; Cooper DA; Carr AD, 2004, 'In vivo nucleoside reverse transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes independent to HIV infection', Antiviral Therapy, 9, pp. L11 - L11

Mallon PW; Sedwell R; Unemori P; Merlin K; McGinley C; Ammaranond P; Peperias M; Rafferty M; Williams KM; Samaras K; Morey AL; Chisholm DJ; Kelleher AD; Cooper DA; Carr AD, 2004, 'Nucleoside reverse transcriptase inhibitors (NRTI) decrease adipocyte and monocyte mitochondrial (mt) messenger RNA transcription in the absence of changes in mtDNA or cell morphology', Antiviral Therapy, 9, pp. L56 - L57

Lomas M; Liauw WS; Packham D; Williams KM; Kelleher AD; Zaunders J; Ward RL, 2004, 'Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy', Annals of Oncology, 15, pp. 324 - 329

Pett SL; Kelleher AD, 2003, 'Cytokine therapies in HIV-1 infection: Present and future', Expert Review of Anti-Infective Therapy, 1, pp. 83 - 96, http://dx.doi.org/10.1586/14787210.1.1.83

Pett SL; Kelleher AD, 2003, 'Cytokine therapies in HIV-1 infection: present and future', Expert Review of Anti-Infective Therapy, 1, pp. 89 - 102

Wang B; Mikhail M; Dyer W; Zaunders J; Kelleher AD; Saksena N, 2003, 'First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection', Virology, 312, pp. 135 - 135

Murray JM; Kaufmann GR; Hodgkin PD; Lewin SR; Kelleher AD; Davenport MP; Zaunders JJ, 2003, 'Naive T cells maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty', Immunology and Cell Biology, 81, pp. 487 - 495

Ammaranond P; Cunningham PH; Oelrichs RB; Suzuki K; Harris C; Leas L; Grulich AE; Cooper DA; Kelleher AD; Harris C, 2003, 'No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1 infection: 1992-2001', AIDS, 17, pp. 264 - 267

Zaunders J; Moutouh-de Parseval L; Kitada S; Reed JC; Rought S; Genini D; Leoni L; Kelleher AD; Cooper DA; Smith DE; Grey PA; Estaquier J; Little S; Richman DD; Corbeil J, 2003, 'Polyclonal proliferation and apoptosis of CCR5+ T Lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2', Journal of Infectious Diseases, 187, pp. 1735 - 1735

Ammaranond P; Cunningham PH; Oelrichs RB; Suzuki K; Harris C; Leas L; Grulich AE; Cooper DA; Kelleher AD; Harris C, 2003, 'Rates of transmission of antiretroviral drug resistant strains of HIV-1', Journal of Clinical Virology, 26, pp. 153 - 153

Allen TM; Kelleher AD; Zaunders J; Walker BD, 2002, 'Structured treatment interruption and beyond', BIOFUTUR, pp. 52 - 58, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000180098300009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Allen TM; Kelleher AD; Zaunders J; Walker BD, 2002, 'Supervised or structured treatment interruption (STI) and beyond...', Biofutur, pp. 52 - 58

Appay V; Zaunders J; Papagno L; Sutton J; Jaramillo AB; Waters A; Eastbrook P; Grey PA; Smith DE; Mcmichael AJ; Cooper DA; Rowland-Jones SL; Kelleher AD, 2002, 'Characterization of CD4(+) CTLs ex vivo', Journal of Immunology, 168, pp. 5954 - 5958

Wang B; Dyer W; Zaunders J; Mikhail M; Sullivan JS; Haddad DM; Williams LA; Harris G; Holt J; Cooper DA; Miranda-Saksena M; Boadle R; Kelleher AD; Saksena NK, 2002, 'Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection', Virology, 304, pp. 246 - 264

Kelleher AD; Sewell WA; Price DM, 2002, 'Dyslipidemia due to retroviral protease inhibitors', Nature Medicine, 8, pp. 308 - 308, http://dx.doi.org/10.1038/nm0402-308a

Cunliffe S; Wyer JR; Sutton J; Lucas M; Harcourt G; Klenerman P; Mcmichael AJ; Kelleher AD, 2002, 'Optimization of peptide linker length in production of MHC Class II/peptide tetrameric complexes increases yield, stability and allows identification of antigen specific CD4+ T cells in PBMC', European Journal of Immunology, 32, pp. 3366 - 3375

Allen TM; Kelleher AD; Zaunders J; Walker BD, 2002, 'STI and beyond: the prospects of boosting anti-HIV immune responses', Trends in Immunology, 23, pp. 456 - 460

Kelleher AD; Booth JL; Sewell AK; Oxenius A; Cerundolo V; McMichael AJ; Phillips RE; Price DA, 2001, 'Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes', AIDS Research and Human Retroviruses, 17, pp. 1063 - 1066, http://dx.doi.org/10.1089/088922201300343744

Kelleher AD; Long C; Holmes EC; Allen RL; Wilson J; Conlon C; Workman C; Shaunak S; Olson K; Goulder P; Brander C; Ogg G; Sullivan JS; Dyer W; Jones I; McMichael AJ; Rowland-Jones S; Phillips RE, 2001, 'Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses', Journal of Experimental Medicine, 193, pp. 375 - 385, http://dx.doi.org/10.1084/jem.193.3.375

Suzuki K; Cunningham P; Harris C; Leas L; Zaunders J; Cooper DA; Kaufmann GR; Pett SL; Kelleher A; Mukaide M; Imai M; Kondo M; Finlayson R, 2001, 'Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine', AIDS Research and Human Retroviruses, 17, pp. 1293 - 1296, http://dx.doi.org/10.1089/088922201750461366

Kaufmann GR; Zaunders J; Murray JM; Kelleher AD; Lewin S; Solomon A; Smith DE; Cooper DA, 2001, 'Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modelling.', AIDS Research and Human Retroviruses, 17, pp. 147 - 159

Kelleher AD; Rowland-Jones SL, 2000, 'Functions of tetramer-stained HIV-specific CD4⁺ and CD8⁺ T cells', Current Opinion in Immunology, 12, pp. 370 - 374, http://dx.doi.org/10.1016/S0952-7915(00)00102-3

McMichael AJ; Ogg G; Wilson J; Callan M; Hambleton S; Appay V; Kelleher T; Rowland-Jones S, 2000, 'Memory CD8⁺ T cells in HIV infection', Philosophical Transactions of the Royal Society B: Biological Sciences, 355, pp. 363 - 367, http://dx.doi.org/10.1098/rstb.2000.0575

Oxenius A; Price DA; Easterbrook PJ; O'Callaghan CA; Kelleher AD; Whelan JA; Sontag G; Sewell AK; Phillips RE, 2000, 'Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8⁺ and CD4⁺ T lymphocytes', Proceedings of the National Academy of Sciences of the United States of America, 97, pp. 3382 - 3387, http://dx.doi.org/10.1073/pnas.97.7.3382

Sewell AK; Price DA; Oxenius A; Kelleher AD; Phillips RE, 2000, 'Cytotoxic T lymphocyte responses to human immunodeficiency virus: Control and escape', Stem Cells, 18, pp. 230 - 244, http://dx.doi.org/10.1634/stemcells.18-4-230

Price DA; Oxenius A; Easterbrook PJ; O'Callaghan CA; Kelleher A; Whelan JA; Sontag G; Sewell AK; Phillips RE, 2000, 'Highly active antiretroviral therapy for primary HIV-1 infection preserves immune function of virus-specific T lymphocytes', Quarterly Journal of Medicine, 93, pp. 769 - 769

Kaufmann GR; Zaunders J; Kelleher AD; Grey PA; Smith DE; Carr AD; Cooper DA, 2000, 'Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection', AIDS, 14, pp. 2543 - 2551

McMichael AJ; Kelleher A, 1999, 'The arrival of HLA class II tetramers', Journal of Clinical Investigation, 104, pp. 1669 - 1770, http://dx.doi.org/10.1172/jci8943

Kelleher AD; Sewell WA; Cooper DA, 1999, 'Effect of protease therapy on cytokine secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected subjects', Clinical and Experimental Immunology, 115, pp. 147 - 152

Zaunders J; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright RH; Smith DE; Grey PA; Vizzard J; Carr AD; Cooper DA, 1999, 'Potent antiretroviral therapy of primary HIV-1 infection: partial normalisation of T lympho-cyte subsets and limited reduction of proviral DNA despite clearance of plasma viremia.', Journal of Infectious Diseases, 180, pp. 320 - 329

Benson EM; Clarkson J; Law MG; Marshall ; Kelleher AD; Smith DE; Patou G; Stewart GA; Cooper DA; French FA, 1999, 'Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific CTL activity in asymptomatic HIV infected individuals.', AIDS Research and Human Retroviruses, 15, pp. 105 - 113

Wilson JDK; Ogg GS; Allen RL; Goulder PJR; Kelleher A; Sewell AK; O'Callaghan CA; Rowland-Jones SL; Callan MFC; McMichael AJ, 1998, 'Oligoclonal expansions of CD8⁺ T cells in chronic HIV infection are antigen specific', Journal of Experimental Medicine, 188, pp. 785 - 790, http://dx.doi.org/10.1084/jem.188.4.785

Murray JM; Kaufmann GR; Kelleher AD; Cooper DA, 1998, 'A model of primary HIV-1 infection', Mathematical Biosciences, 154, pp. 57 - 85

Carr A; Kelleher A, 1998, 'Can Antiretroviral Therapy 'treat' Opportunistic Infections in Patients with HIV Infection', HIV Advances in Research and Therapy, 8

Kelleher AD; Roggensack M; Emery S; Carr AD; French MA; Cooper DA, 1998, 'Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens', Clinical and Experimental Immunology, 113, pp. 85 - 91

Kaufmann GR; Cunningham PH; Kelleher AD; Zaunders J; Carr AD; Vizzard J; Law MG; Cooper DA; Catchpole BR; Baker D; Beveridge A; Bloch M; Byrne J; Doong N; Duncombe CJ; Finlayson R; Genn W; Kidd J; Mcfarlane R; Mcmurchie M; Mcnulty A; Pethebridge A; Quan D; Robertson M, 1998, 'Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection', Journal of Infectious Diseases, 178, pp. 1812 - 1815

Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker AC; Gow I; Mcmurchie M; Harris JA; Patou G; Cooper DA; Duncombe CJ; Bloch M; Quan D; Beveridge A; Genn B; Pethebridge A; Todhunter L; Baker D; Mcfarlane R; Mindel A; Knox J; O Connor C; Mitchell JR; Meese P; Chenworth I; Anderson JS; Roth N, 1998, 'Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects', AIDS, 12, pp. 175 - 182

Kelleher AD; Al-Harthi L; Landay AL, 1997, 'Immunological effects of antiretroviral and immune therapies for HIV.', AIDS (London, England), 11 Suppl A

Carr A; Cunningham P; Kelleher A, 1997, 'Diagnosis and treatment of primary HIV infection', J HIV Combination Therapy, pp. 49 - 56

Kelleher A, 1997, 'Restoring Immune Function through Antiretroviral Therapy', Clinical Insight, pp. 1 - 1

Kelleher S; Emery S; Cunningham PH; Duncombe CJ; Carr AD; Golding H; Forde S; Hudson J; Roggensack M; Forrest BD; Cooper DA, 1997, 'Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection', AIDS Research and Human Retroviruses, 13, pp. 29 - 32

Back to profile page